行情

NTLA

NTLA

Intellia
NASDAQ

实时行情|Nasdaq Last Sale

14.64
+0.39
+2.74%
盘后: 14.64 0 0.00% 16:07 09/16 EDT
开盘
14.19
昨收
14.25
最高
14.71
最低
14.15
成交量
23.47万
成交额
--
52周最高
32.95
52周最低
11.03
市值
7.11亿
市盈率(TTM)
-7.3101
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NTLA 新闻

  • 本周开庭!苹果拟对抗欧盟140亿美元天价税单
  • 新浪科技.13小时前
  • 沪指震荡微跌 沙特石油设施遇袭、油价一度跳升20%
  • 新浪财经.13小时前
  • 沙特阿美据称仍在推进IPO工作 尽管设施受到重创
  • 新浪财经综合.13小时前
  • 若沙特局势恶化 韩国将考虑释放战略石油储备
  • 新浪财经综合.13小时前

更多

所属板块

生物技术和医学研究
+0.91%
制药与医学研究
-0.17%

热门股票

名称
价格
涨跌幅

NTLA 简况

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.
展开

Webull提供Intellia Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。